Pfizer (PFE 0.82%) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 candidate for weight management. The stock has been trading about 63% below its all-time high. The danuglipron program's termination is disappointing, but it won't be the end of Pfizer's attempt to develop blockbuster weight-management drugs. The company has an oral glucose-dependent insulinotropic polypeptide recepto ...